Brosig Cheryl L, Bear Laurel, Allen Sydney, Hoffmann Raymond G, Pan Amy, Frommelt Michele, Mussatto Kathleen A
Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI; Herma Heart Center, Children's Hospital of Wisconsin, Milwaukee, WI.
Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI; Herma Heart Center, Children's Hospital of Wisconsin, Milwaukee, WI.
J Pediatr. 2017 Apr;183:80-86.e1. doi: 10.1016/j.jpeds.2016.12.044. Epub 2017 Jan 9.
To describe preschool neurodevelopmental outcomes of children with complex congenital heart disease (CHD), who were evaluated as part of a longitudinal cardiac neurodevelopmental follow-up program, as recommended by the American Heart Association and the American Academy of Pediatrics, and identify predictors of neurodevelopmental outcomes in these children.
Children with CHD meeting the American Heart Association/American Academy of Pediatrics high-risk criteria for neurodevelopmental delay were evaluated at 4-5 years of age. Testing included standardized neuropsychological measures. Parents completed measures of child functioning. Scores were compared by group (single ventricle [1V]; 2 ventricles [2V]; CHD plus known genetic condition) to test norms and classified as: normal (within 1 SD of mean); at risk (1-2 SD from mean); and impaired (>2 SD from mean).
Data on 102 patients were analyzed. Neurodevelopmental scores did not differ based on cardiac anatomy (1V vs 2V); both groups scored lower than norms on fine motor and adaptive behavior skills, but were within 1 SD of norms. Patients with genetic conditions scored significantly worse than 1V and 2V groups and test norms on most measures.
Children with CHD and genetic conditions are at greatest neurodevelopmental risk. Deficits in children with CHD without genetic conditions were mild and may not be detected without formal longitudinal testing. Parents and providers need additional education regarding the importance of developmental follow-up for children with CHD.
描述患有复杂先天性心脏病(CHD)儿童的学前神经发育结局,这些儿童是按照美国心脏协会和美国儿科学会的建议,作为一项纵向心脏神经发育随访计划的一部分接受评估的,并确定这些儿童神经发育结局的预测因素。
对符合美国心脏协会/美国儿科学会神经发育延迟高危标准的CHD儿童在4至5岁时进行评估。测试包括标准化神经心理学测量。家长完成儿童功能测量。按组(单心室[1V];双心室[2V];CHD合并已知遗传疾病)比较分数以检验常模,并分类为:正常(在均值的1个标准差范围内);有风险(距均值1 - 2个标准差);以及受损(距均值>2个标准差)。
分析了102例患者的数据。神经发育分数不因心脏解剖结构(1V与2V)而异;两组在精细运动和适应性行为技能方面的得分均低于常模,但在常模的1个标准差范围内。患有遗传疾病的患者在大多数测量指标上的得分明显低于1V和2V组以及测试常模。
患有CHD和遗传疾病的儿童神经发育风险最高。无遗传疾病的CHD儿童的缺陷较轻,若无正式的纵向测试可能无法检测到。家长和医疗服务提供者需要接受关于CHD儿童发育随访重要性的更多教育。